Pentoxifylline in Patients With Ulcerative Colitis

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorIhab Elsayed Hassan

About this trial

Ulcerative colitis (UC) is a persistent, idiopathic form of inflammatory bowel disease (IBD) marked by uninterrupted inflammation of the colon's mucosal lining, usually starting at the rectum and progressing proximally in a continuous manner. It manifests clinically with recurrent episodes of abdominal pain, bloody diarrhea, urgency, tenesmus, and weight loss. The precise cause of UC is still unknown; however, it is thought to arise from a multifactorial interaction involving genetic susceptibility, immune system dysregulation, disturbances in gut microbiota composition, and various environmental factors.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Both male and female will be included

Negative pregnancy test and effective contraception.

Mild and moderate UC patients

Disqualifiers

Breast feeding

Significant liver and kidney function abnormalities

Diabetic patients

Colorectal cancer patients

Trial design

Treatments tested in this trial

  • Mesalamine
  • Pentoxifylline

Treatment groups

60 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ihab Elsayed Hassan

Lead sponsor

Tanta University

Sponsor institution